BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Response to oxidative stress, Obesity, Adipose tissue, Anticancer prodrugs, PTEN)
Bookmark Forward

QuickView for PRF1 (gene)


Body Atlas

Most Correlated Tissues

  1. Natural killer cell of peripheral blood
  2. T Lymphocyte (CD8+) of peripheral blood
  3. Whole blood
  4. Spleen
  5. Mononuclear cell of peripheral blood
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Hemophagocytic lymphohistiocytosis
  2. Drug resistance
  3. B-cell lymphoma
  4. Contact dermatitis
  5. Other lymphoma
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. sanguinarine
  2. CEP 14083
  3. R 848
  4. Aphidicolin
  5. artesunate
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. FGFR1
  2. ANKRD52
  3. SLC9A3R2
  4. PRAF2
  5. GPX1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Preparation of Cytolysin A (ClyA) Nanopores.
  2. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocyti…
  3. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induc…
  4. MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1.
  5. PRF1 as a prognostic gene for lymphatic metastasis in skin melanoma.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. PRF+1% MF for Class II Mandibular Furcation Defects
  2. A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in I…
  3. Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative…
  4. Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
  5. Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphoh…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.